Incyte (INCY) Net Cash Flow (2010 - 2026)
Incyte posted quarterly Net Cash Flow of $366.0 million for Q1 2026, up 43.81% year-on-year from $254.5 million in Q1 2025, and down 43.14% on a QoQ basis from $643.6 million in Q4 2025.
Incyte (INCY) has 17 years of Net Cash Flow data on file, last reported at $366.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 43.81% year-over-year to $366.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 208.24% YoY), and the FY2025 full-year result was $1.4 billion, up 192.36% from the prior year.
- Net Cash Flow for Q1 2026 stood at $366.0 million, down from $643.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $643.6 million in Q4 2025 and bottomed at -$2.4 billion in Q2 2024.
- The 5-year median for Net Cash Flow is $253.7 million (2022), against an average of $82.9 million.
- Peak annual rise in Net Cash Flow reached 6016.68% in 2024, while the deepest fall reached 856.15% in 2024.
- A 5-year view of Net Cash Flow shows it stood at $260.3 million in 2022, then tumbled by 102.47% to -$6.4 million in 2023, then soared by 6016.68% to $380.1 million in 2024, then soared by 69.31% to $643.6 million in 2025, then slumped by 43.14% to $366.0 million in 2026.
- The last three Net Cash Flow figures came in at $366.0 million (Q1 2026), $643.6 million (Q4 2025), and $499.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 365.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 365.97 Mn |
| Mar 31, 2026 | 365.97 Mn |
| Dec 31, 2025 | 643.62 Mn |
| Dec 31, 2025 | 643.62 Mn |
| Sep 30, 2025 | 499.20 Mn |
| Sep 30, 2025 | 499.20 Mn |
| Jun 30, 2025 | 14.62 Mn |
| Jun 30, 2025 | 14.62 Mn |
| Mar 31, 2025 | 254.49 Mn |
| Mar 31, 2025 | 254.49 Mn |
| Dec 31, 2024 | 380.15 Mn |
| Dec 31, 2024 | 380.15 Mn |
| Sep 30, 2024 | 316.79 Mn |
| Sep 30, 2024 | 316.79 Mn |
| Jun 30, 2024 | -2.36 Bn |
| Jun 30, 2024 | -2.36 Bn |
| Mar 31, 2024 | 133.29 Mn |
| Mar 31, 2024 | 133.29 Mn |
| Dec 31, 2023 | -6.43 Mn |
| Dec 31, 2023 | -6.43 Mn |
| Sep 30, 2023 | 93.39 Mn |
| Sep 30, 2023 | 93.39 Mn |
| Jun 30, 2023 | 311.97 Mn |
| Jun 30, 2023 | 311.97 Mn |
| Mar 31, 2023 | -130.15 Mn |
| Mar 31, 2023 | -130.15 Mn |
| Dec 31, 2022 | 260.27 Mn |
| Dec 31, 2022 | 260.27 Mn |
| Sep 30, 2022 | 253.67 Mn |
| Sep 30, 2022 | 253.67 Mn |
| Jun 30, 2022 | 177.58 Mn |
| Jun 30, 2022 | 177.58 Mn |
| Mar 31, 2022 | 199.09 Mn |
| Mar 31, 2022 | 199.09 Mn |
| Dec 31, 2021 | 58.31 Mn |
| Dec 31, 2021 | 58.31 Mn |
| Sep 30, 2021 | 203.00 Mn |
| Sep 30, 2021 | 203.00 Mn |
| Jun 30, 2021 | 127.48 Mn |
| Jun 30, 2021 | 127.48 Mn |
| Mar 31, 2021 | 159.18 Mn |
| Mar 31, 2021 | 159.18 Mn |
| Dec 31, 2020 | 16.46 Mn |
| Dec 31, 2020 | 16.46 Mn |
| Sep 30, 2020 | 168.59 Mn |
| Sep 30, 2020 | 168.59 Mn |
| Jun 30, 2020 | 282.53 Mn |
| Jun 30, 2020 | 282.53 Mn |
| Mar 31, 2020 | -789.48 Mn |
| Mar 31, 2020 | -789.48 Mn |
| Dec 31, 2019 | 130.91 Mn |
| Dec 31, 2019 | 130.91 Mn |
| Sep 30, 2019 | 285.59 Mn |
| Sep 30, 2019 | 285.59 Mn |
| Jun 30, 2019 | 116.82 Mn |
| Jun 30, 2019 | 116.82 Mn |
| Mar 31, 2019 | 135.59 Mn |
| Mar 31, 2019 | 135.59 Mn |
| Dec 31, 2018 | 51.80 Mn |
| Dec 31, 2018 | 51.80 Mn |
| Sep 30, 2018 | 183.71 Mn |
| Sep 30, 2018 | 183.71 Mn |
| Jun 30, 2018 | 34.04 Mn |
| Jun 30, 2018 | 34.04 Mn |
| Mar 31, 2018 | -5.10 Mn |
| Mar 31, 2018 | -5.10 Mn |
| Dec 31, 2017 | -228.55 Mn |
| Dec 31, 2017 | -228.55 Mn |
| Sep 30, 2017 | 676.28 Mn |
| Sep 30, 2017 | 676.28 Mn |
| Jun 30, 2017 | 90.01 Mn |
| Jun 30, 2017 | 90.01 Mn |
| Mar 31, 2017 | -290.50 Mn |
| Mar 31, 2017 | -290.50 Mn |
| Dec 31, 2016 | 58.22 Mn |
| Dec 31, 2016 | 58.22 Mn |
| Sep 30, 2016 | 92.45 Mn |
| Sep 30, 2016 | 92.45 Mn |
| Jun 30, 2016 | -169.95 Mn |
| Jun 30, 2016 | -169.95 Mn |
| Mar 31, 2016 | 136.18 Mn |
| Mar 31, 2016 | 136.18 Mn |
| Dec 31, 2015 | 75.64 Mn |
| Dec 31, 2015 | 75.64 Mn |
| Sep 30, 2015 | 6.12 Mn |
| Sep 30, 2015 | 6.12 Mn |
| Jun 30, 2015 | 17.86 Mn |
| Jun 30, 2015 | 17.86 Mn |
| Mar 31, 2015 | -30.48 Mn |
| Mar 31, 2015 | -30.48 Mn |
| Dec 31, 2014 | 70.30 Mn |
| Dec 31, 2014 | 70.30 Mn |
| Sep 30, 2014 | -24.26 Mn |
| Sep 30, 2014 | -24.26 Mn |
| Jun 30, 2014 | -30.32 Mn |
| Jun 30, 2014 | -30.32 Mn |
| Mar 31, 2014 | -34.84 Mn |
| Mar 31, 2014 | -34.84 Mn |
| Dec 31, 2013 | 199.31 Mn |
| Dec 31, 2013 | 199.31 Mn |
| Sep 30, 2013 | 13.92 Mn |
| Sep 30, 2013 | 13.92 Mn |
| Jun 30, 2013 | -7.61 Mn |
| Jun 30, 2013 | -7.61 Mn |
| Mar 31, 2013 | 41.76 Mn |
| Mar 31, 2013 | 41.76 Mn |
| Dec 31, 2012 | -15.03 Mn |
| Dec 31, 2012 | -15.03 Mn |
| Sep 30, 2012 | -18.48 Mn |
| Sep 30, 2012 | -18.48 Mn |
| Jun 30, 2012 | 25.71 Mn |
| Jun 30, 2012 | 25.71 Mn |
| Mar 31, 2012 | -41.31 Mn |
| Mar 31, 2012 | -41.31 Mn |
| Dec 31, 2011 | -39.16 Mn |
| Dec 31, 2011 | -39.16 Mn |
| Sep 30, 2011 | -46.75 Mn |
| Sep 30, 2011 | -46.75 Mn |
| Jun 30, 2011 | -18.77 Mn |
| Jun 30, 2011 | -18.77 Mn |
| Mar 31, 2011 | -40.07 Mn |
| Mar 31, 2011 | -40.07 Mn |
| Dec 31, 2010 | 29.11 Mn |
| Dec 31, 2010 | 29.11 Mn |
| Sep 30, 2010 | -25.28 Mn |
| Sep 30, 2010 | -25.28 Mn |
| Jun 30, 2010 | 9.34 Mn |
| Jun 30, 2010 | 9.34 Mn |
| Mar 31, 2010 | -45.08 Mn |
| Mar 31, 2010 | -45.08 Mn |